All In Biotech

Drug Trial Radar · NCT06758401

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 714 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

714

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

Sep 5, 2028

Study completion Mar 1, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.

Conditions

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions

  • Sigvotatug VedotinDrug

    MMAE-Antibody Drug Conjugate targeting Integrin Beta-6

  • PembrolizumabDrug

    Anti-PD-(L)1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Baseline to date of death from any cause (Approximately 2 years).
  2. Progression Free Survival (PFS) assessed by blinded independent central review (BICR)Time frame: From Baseline to to date of first documentation of progression OR death (Approximately 2 years).

Locations

392 sites in 31 countries. Site status is shown where the registry gives one.

  • Fairbanks Cancer Care Physicians, PC

    Fairbanks, Alaska · Not yet recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center

    Fullerton, California · Recruiting

  • Providence St. Jude Medical Center

    Fullerton, California · Recruiting

  • St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test)

    Fullerton, California · Recruiting

  • Intermountain Health Cancer Center Lutheran Hospital

    Golden, Colorado · Recruiting

  • Cancer Centers of Colorado St. Mary's Regional Hospital

    Grand Junction, Colorado · Recruiting

  • Intermountain Health St. Mary's Regional Hospital

    Grand Junction, Colorado · Recruiting

  • Intermountain Health

    Grand Junction, Colorado · Recruiting

  • Intermountain Health Lutheran Hospital

    Wheat Ridge, Colorado · Recruiting

  • Washington DC Veterans Affairs Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • BRCR Global

    Plantation, Florida · Recruiting

  • Endeavor Health

    Elmhurst, Illinois · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Advocate Medical Group - Libertyville Oncology

    Libertyville, Illinois · Recruiting

  • Endeavor Health

    Naperville, Illinois · Recruiting

  • Hope and Healing Cancer Services

    New Lenox, Illinois · Recruiting

  • Advocate Christ Medical Center

    Oak Lawn, Illinois · Recruiting

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois · Recruiting

  • Saint Luke's South Hospital

    Overland Park, Kansas · Recruiting

  • Maine Medical Center

    Portland, Maine · Recruiting

  • MaineHealth Cancer Care and Blood Disorders Scarborough

    Scarborough, Maine · Recruiting

  • MaineHealth Cancer Care and IV Therapy - South Portland

    South Portland, Maine · Recruiting

  • Southcoast Centers for Cancer Care

    Fairhaven, Massachusetts · Recruiting

  • Southcoast Centers for Cancer Care

    Fall River, Massachusetts · Recruiting

  • Corewell Health - Butterworth Hospital

    Grand Rapids, Michigan · Recruiting

  • Corewell Health - Lemmen Holton Cancer Pavilion

    Grand Rapids, Michigan · Recruiting

  • Corewell Health - Research Specimen Processing Area

    Grand Rapids, Michigan · Recruiting

  • Corewell Health Investigational Drug Services

    Grand Rapids, Michigan · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Recruiting

  • Minnesota Oncology Hematology, PA

    Burnsville, Minnesota · Recruiting

  • Minnesota Oncology Hematology PA

    Coon Rapids, Minnesota · Recruiting

  • M Health Fairview Cancer Clinic-Edina

    Edina, Minnesota · Recruiting

  • Minnesota Oncology Hematology PA

    Edina, Minnesota · Recruiting

  • Minnesota Oncology Hematology PA

    Maple Grove, Minnesota · Recruiting

  • M Health Fairview St. John's Hospital

    Maplewood, Minnesota · Recruiting

  • Minnesota Oncology Hematology PA

    Maplewood, Minnesota · Recruiting

  • Hennepin County Medical Center

    Minneapolis, Minnesota · Recruiting

  • North Memorial Health Cancer Center

    Robbinsdale, Minnesota · Recruiting

Showing 40 of 392 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.